Skip to main content
SpringerLink
Log in

Patientenberichtete Endpunkte in der Kopf-Hals-Tumortherapie: Relevanz, Herausforderungen und Nutzen

Patient-reported outcomes in head and neck cancer treatment: relevance, challenges, and benefit

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Neben dem möglichst langen Überleben spielt die Lebensqualität nach einer Krebserkrankung immer mehr eine Rolle für die Betroffenen. Die verschiedenen Lebensqualitätsbereiche sind komplex und werden individuell unterschiedlich gewichtet. Nicht nur für die Patient*innen, sondern auch für Ärzt*innen, die pharmazeutische Industrie und auch für die Zulassungsbehörden stellt sich die Frage: Wie kann man in klinischen Studien verlässlich feststellen, wie die Lebensqualität der Patient*innen ist? Dazu werden sorgfältig entwickelte und validierte Fragbögen benötigt, die Patient-Reported Outcome Measures (PROM). Die Herausforderung hierbei ist, Ergebnisse entsprechender Studien dazu nutzen zu können, die gemeinsame Entscheidungsfindung zu verbessern. Neben klinisch bekannten Faktoren wie Allgemein- und Ernährungszustand ist die Lebensqualität ebenfalls ein prognostischer Faktor für das Überleben im Rahmen von onkologischen Erkrankungen. Insofern spielt die Lebensqualität auch vor diesem Hintergrund eine klinisch bedeutsame Rolle und sollte entsprechend berücksichtigt werden.

Abstract

Next to overall survival, quality of life is becoming more and more pivotal for cancer patients. The various domains of quality of life are complex and have different value to each patient. However, not only patients but also health care professionals, the pharmaceutical industry, and regulatory bodies ask: How can quality of life be reliably ascertained in clinical trials? For this purpose, carefully developed and validated specific questionnaires are needed: the patient-reported outcome measures (PROMs). A key challenge is to define how results based on PROMs can be used for shared decision-making. Next to clinical factors such as health and nutritional status, quality of life acts as a prognostic factor for overall survival in cancer. Thus, it is crucial to take quality of life into account in daily clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aaronson N, Ahmedzai S, Bergmann B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    CAS  PubMed  Google Scholar 

  2. Bergelt C, Scholl I, Härter M (2016) Chancen und Barrieren partizipativer Entscheidungsfindung in der Onkologie. Forum DKG 31:140–143

    Google Scholar 

  3. Bergner M, Bobbitt RA, Carter WB et al (1981) The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19:787–805

    CAS  PubMed  Google Scholar 

  4. Bjordal K, De Graeff A (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer 36:1796–1807

    CAS  PubMed  Google Scholar 

  5. Böhme S, Singer S, Kauffmann S et al (2022) Es braucht neue Ansätze für Lebensqualitätsdaten. Monit Versorgungsforsch 15:43–47

    Google Scholar 

  6. Brazier J, Deverill M (1999) A checklist for judging preference-based measures of health related quality of life: Learning from psychometrics. Health Econ 8:41–51

    CAS  PubMed  Google Scholar 

  7. Bundesgesundheitsministerium (2020) Ziele des Nationalen Krebsplans

    Google Scholar 

  8. Bussmann L, Laban S, Wittekindt C et al (2020) Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC). BMC Cancer 20:701

    PubMed  PubMed Central  Google Scholar 

  9. Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570–579

    CAS  PubMed  Google Scholar 

  10. Chen AY, Frankowski R, Bishop-Leone J et al (2001) The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer—The M. D. Anderson dysphagia inventory. Arch Otolaryngol Neck Surg 127:870–876

    CAS  Google Scholar 

  11. Cocks K, Contente M, Simpson S et al (2019) A Q‑TWiST analysis comparing Nivolumab and therapy of investigator’s choice in patients with recurrent/metastatic platinum-refractory squamous cell carcinoma of the head and neck. PharmacoEconomics 37:1041–1047

    PubMed  PubMed Central  Google Scholar 

  12. De Haes JC, Van Knippenberg FC, Neijt JP (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62:1034–1038

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Eichler M, Singer S, Hentschel L et al (2022) Health Related Quality of Life is a prognostic factor for 1‑year-survival in sarcoma patients—Results of a Nationwide Observational Study (PROSa). Br J Cancer 126:1346–1354

    PubMed  PubMed Central  Google Scholar 

  14. Elwyn G, Durand MA, Song JL et al (2017) A three-talk model for shared decision making: multistage consultation process. BMJ 359:7

    Google Scholar 

  15. Fahsl S, Keszte J, Boehm A et al (2012) Clinical relevance of quality of life data in laryngectomized patients. Laryngoscope 122:1532–1538

    PubMed  Google Scholar 

  16. Fried TR, Bradley EH, Towle VR et al (2002) Understanding the treatment preferences of seriously ill patients. N Engl J Med 346:1061–1066

    PubMed  Google Scholar 

  17. Group TE (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208

    Google Scholar 

  18. Group W (1994) The development of the WHO quality of life assessment instrument (WHOQOL). In: Orley J, Kukyen W (Hrsg) Quality of life assessment:international perspectives. Springer, Heidelberg

    Google Scholar 

  19. Hajdu SF, Wessel I, Dalton SO et al (2022) Swallowing exercise during head and neck cancer treatment: results of a randomized trial. Dysphagia 37:749–762

    PubMed  Google Scholar 

  20. Hassan SJ, Weymuller EA Jr. (1993) Assessment of quality of life in head and neck cancer patients. Head Neck 15:485–496

    CAS  PubMed  Google Scholar 

  21. Hoffmann TK (2022) The ORATOR trials—an update: Primary surgery or radiotherapy for HPV-associated oropharyngeal cancer. HNO 70:579–580

    PubMed  Google Scholar 

  22. John MT, Patrick DL, Slade GD (2002) The German version of the oral health impact profile—translation and psychometric properties. Eur J Oral Sci 110:425–433

    PubMed  Google Scholar 

  23. Kaplan RM, Debon M, Anderson BF (1991) Effects of number of rating scale points upon utilities in a quality of well-being scale. Med Care 29:1061–1064

    CAS  PubMed  Google Scholar 

  24. Kemmler G, Gamper E, Nerich V et al (2019) German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30. Qual Life Res 28:3197–3211

    PubMed  PubMed Central  Google Scholar 

  25. Koerber SA, Seither B, Slynko A et al (2019) Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. Tumori 105:174–180

    PubMed  Google Scholar 

  26. Lapen K, King C, Braunstein LZ et al (2022) A comparison of patient- and clinician-reported acute toxic effects during radiation therapy for primary breast cancer. Int J Radiat Oncol Biol Phys 114:301–309

    PubMed  Google Scholar 

  27. List MA, D’antonio LL, Cella DF et al (1996) The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity. Cancer 77:2294–2301

    CAS  PubMed  Google Scholar 

  28. List MA, Rutherford JL, Stracks J et al (2004) Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck 26:163–170

    PubMed  Google Scholar 

  29. List MA, Stracks J, Colangelo L et al (2000) How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol 18:877–884

    CAS  PubMed  Google Scholar 

  30. Loser A, Avanesov M, Thieme A et al (2022) Nutritional status impacts quality of life in head and neck cancer patients undergoing (chemo)radiotherapy: results from the prospective HEADNUT trial. Nutr Cancer 74:2887–2895

    PubMed  Google Scholar 

  31. Mchorney CA, Bricker DE, Kramer AE et al (2000) The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: I. Conceptual foundation and item development. Dysphagia 15:115–121

    CAS  PubMed  Google Scholar 

  32. Mchorney CA, Bricker DE, Robbins J et al (2000) The SWAL-QOL outcomes tool for oropharyngeal dysphagia in adults: II. Item reduction and preliminary scaling. Dysphagia 15:122–133

    CAS  PubMed  Google Scholar 

  33. Mchorney CA, Ware JE Jr., Lu JF et al (1994) The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32:40–66

    CAS  PubMed  Google Scholar 

  34. Mehanna HM, De Boer MF, Morton RP (2008) The association of psycho-social factors and survival in head and neck cancer. Clin Otolaryngol 33:83–89

    CAS  PubMed  Google Scholar 

  35. Messing BP, Ward EC, Lazarus CL et al (2017) Prophylactic swallow therapy for patients with head and neck cancer undergoing chemoradiotherapy: a randomized trial. Dysphagia 32:487–500

    PubMed  PubMed Central  Google Scholar 

  36. Meyer A, Dietz A, Wollbrück D et al (2012) Schluckstörungen nach Kehlkopfteilresektion: Auftrittshäufigkeit und Prädiktoren. HNO 60:892–900

    CAS  PubMed  Google Scholar 

  37. Meyer F, Fortin A, Gelinas M et al (2009) Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol 27:2970–2976

    PubMed  Google Scholar 

  38. Mogadas S, Busch CJ, Pflug C et al (2020) Influence of radiation dose to pharyngeal constrictor muscles on late dysphagia and quality of life in patients with locally advanced oropharyngeal carcinoma. Strahlenther Onkol 196:522–529

    CAS  PubMed  Google Scholar 

  39. Mowery YM, Salama JK (2022) Interpreting ORATOR: lessons learned from a randomized comparison of primary surgical and radiation approaches for early-stage oropharyngeal cancer. J Clin Oncol 40:814–817

    PubMed  Google Scholar 

  40. Musoro J, Coens C, Singer S et al (2020) Minimally important differences for interpreting European Organisation for Research and Treatment for Cancer Quality of life Core Questionnaire scores in patients with head and neck cancer. Head Neck 42:3141–3152

    PubMed  Google Scholar 

  41. Nguyen H, Butow P, Dhillon H et al (2020) Using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine head and neck cancer care: What do health professionals perceive as barriers and facilitators? J Med Imaging Radiat Oncol 64:704–710

    PubMed  Google Scholar 

  42. Nichols AC, Theurer J, Prisman E et al (2019) Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol 20:1349–1359

    CAS  PubMed  Google Scholar 

  43. Nichols AC, Theurer J, Prisman E et al (2022) Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol 40:866–875

    CAS  PubMed  Google Scholar 

  44. Palma DA, Prisman E, Berthelet E et al (2022) Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma: the ORATOR2 phase 2 randomized clinical trial. JAMA Oncol 8:1–7

    PubMed  PubMed Central  Google Scholar 

  45. Quinten C, Coens C, Mauer M et al (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865–871

    PubMed  Google Scholar 

  46. Rammant E, Ost P, Swimberghe M et al (2019) Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial. Strahlenther Onkol 195:393–401

    PubMed  Google Scholar 

  47. Reeve B, Wyrwich K, Wu A et al (2013) ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 22:1889–1905

    PubMed  Google Scholar 

  48. Rischin D, Harrington KJ, Greil R et al (2022) Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol 128:105815

    CAS  PubMed  Google Scholar 

  49. Rogers SN, Barber B (2017) Using PROMs to guide patients and practitioners through the head and neck cancer journey. Patient Relat Outcome Meas 8:133–142

    PubMed  PubMed Central  Google Scholar 

  50. Rogers SN, Gwanne S, Lowe D et al (2002) The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck 24:521–529

    PubMed  Google Scholar 

  51. Rosenthal DI, Mendoza TR, Chambers MS et al (2007) Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 29:923–931

    PubMed  Google Scholar 

  52. Roth AJ, Kornblith AB, Batel-Copel L et al (1998) Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 82:1904–1908

    CAS  PubMed  Google Scholar 

  53. Rummans TA, Bostwick JM, Clark MM et al (2000) Maintaining quality of life at the end of life. Mayo Clin Proc 75:1305–1310

    CAS  PubMed  Google Scholar 

  54. Sherbourne CD, Sturm R, Wells KB (1999) What outcomes matter to patients? J Gen Intern Med 14:357–363

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Shune SE, Karnell LH, Karnell MP et al (2012) Association between severity of dysphagia and survival in patients with head and neck cancer. Head Neck 34:776–784

    PubMed  Google Scholar 

  56. Singer S, Amdal CD, Hammerlid E et al (2019) International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. Head Neck 41:1725–1737

    PubMed  Google Scholar 

  57. Singer S, Araújo C, Arraras J et al (2015) Measuring quality of life in head and neck cancer patients—Update of the EORTC QLQ-H&N module, phase III. Head Neck 37:1358–1367

    PubMed  Google Scholar 

  58. Singer S, Danker H, Guntinas-Lichius O et al (2014) Quality of life before and after total laryngectomy—Results of a multi-centre prospective cohort study. Head Neck 36:359–368

    PubMed  Google Scholar 

  59. Singer S, Hammerlid E, Tomaszewska IM et al (2022) Methodological approach for determining the minimal important difference and minimal important change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the swallowing scale. Qual Life Res 31:841–853

    PubMed  Google Scholar 

  60. Singer S, Jordan S, Locati L et al (2017) The EORTC module for quality of life in patients with thyroid cancer—phase III. Endocr Relat Cancer 24:197–207

    PubMed  Google Scholar 

  61. Singer S, Papsdorf K, Gäbelein G et al (2015) Lebensqualität als prognostischer Faktor für das Überleben bei Patienten mit Ösophaguskarzinom. Onkologe 21:57–61

    Google Scholar 

  62. Singer S, Vogel H‑J, Guntinas-Lichius O et al (2019) Multicenter prospective study on the use and outcome of rehabilitation after total laryngectomy in Germany. Head Neck 41:1070–1079

    PubMed  Google Scholar 

  63. Slade GD (1998) Assessing change in quality of life using the oral health impact profile. Commun Dent Oral Epidemiol 26:52–61

    CAS  Google Scholar 

  64. Smets EMA, Garssen B, Bonke B et al (1995) The multidimensional fatigue inventory (MFI) Psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315–325

    CAS  PubMed  Google Scholar 

  65. Steen-Olsen EB, Stormoen DR, Kristensen CA et al (2022) Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires. Eur Arch Otorhinolaryngol 279:4199–4206

    PubMed  Google Scholar 

  66. Stein JD, Newman-Casey PA, Mrinalini T et al (2014) Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 121:936–945

    PubMed  Google Scholar 

  67. Taylor K, Amdal CD, Bjordal K et al (2023) Serious long-term effects of head and neck cancer from the survivors’ point of view. Healthcare 11:906

    PubMed  PubMed Central  Google Scholar 

  68. Teckie S, Gross ND (2022) The ORATOR trials have spoken-where do we go from here? JAMA Oncol 8:1–2

    PubMed  Google Scholar 

  69. Tribius S, Raguse MC, Voigt C et al (2015) Residual deficits in quality of life one year after intensity-modulated radiotherapy in patients with locally advanced head and neck cancer: results of a prospective study. Strahlenther Onkol 191:501–510

    PubMed  Google Scholar 

  70. Vaandering A, Jansen N, Weltens C et al (2023) Radiotherapy-specific quality indicators at national level: How to make it happen. Radiother Oncol 178:9

    Google Scholar 

  71. Ware JE Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483

    PubMed  Google Scholar 

  72. Yeung AR, Pugh SL, Klopp AH et al (2020) Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG oncology RTOG 1203 study. J Clin Oncol 38:1685

    PubMed  PubMed Central  Google Scholar 

  73. Zebralla V, Müller J, Wald T et al (2020) Obtaining patient-reported outcomes electronically with “Oncofunction” in head and neck cancer patients during aftercare. Front Oncol 10, Article Number 549915. https://doi.org/10.3389/fonc.2020.549915

  74. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Epidemiologie und Versorgungsforschung, Institut für Medizinische Biometrie, Epidemiologie und Informatik, Universitätsmedizin Mainz, 55101, Mainz, Deutschland

    Susanne Singer

  2. Institut für Medizinische Psychologie, Universitätsmedizin Greifswald, Greifswald, Deutschland

    Corinna Bergelt

  3. Hermann-Holthusen-Institut für Strahlentherapie, Asklepios-Klinik St. Georg, Hamburg, Deutschland

    Silke Tribius

  4. Klinik und Poliklinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsmedizin Ulm, Ulm, Deutschland

    Simon Laban

  5. Klinik und Poliklinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsmedizin Greifswald, Greifswald, Deutschland

    Chia-Jung Busch

  6. Asklepios Tumorzentrum Hamburg, Hamburg, Deutschland

    Silke Tribius

Authors
  1. Susanne Singer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Corinna Bergelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silke Tribius
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Simon Laban
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chia-Jung Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Singer.

Ethics declarations

Interessenkonflikt

S. Singer, C. Bergelt, S. Tribius, S. Laban und C.-J. Busch geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singer, S., Bergelt, C., Tribius, S. et al. Patientenberichtete Endpunkte in der Kopf-Hals-Tumortherapie: Relevanz, Herausforderungen und Nutzen. HNO 71, 592–598 (2023). https://doi.org/10.1007/s00106-023-01325-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-023-01325-7

Schlüsselwörter

Keywords

Search

Navigation